Next Article in Journal
Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease
Previous Article in Journal
Scale-Up Production of Type O and A Foot-and-Mouth Disease Bivalent Vaccine and Its Protective Efficacy in Pigs
Review

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans

1
School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou 310053, China
2
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
3
Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China
*
Author to whom correspondence should be addressed.
Academic Editor: Seth Pincus
Vaccines 2021, 9(6), 588; https://doi.org/10.3390/vaccines9060588
Received: 22 April 2021 / Revised: 24 May 2021 / Accepted: 28 May 2021 / Published: 2 June 2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) pose a great threat to humanity. Every pandemic involving these coronaviruses has seriously affected human health and economic development. Currently, there are no approved therapeutic drugs against their infections. Therefore, the development of vaccines is particularly important to combat these coronaviruses. In this review, we summarized and analyzed the progress of vaccines against SARS-CoV, MERS-CoV, and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, nucleic acid vaccines, and viral vector vaccines. In addition, we compared the levels of neutralizing antibodies in the serum of patients with these three kinds of coronaviruses at different stages, and their ability and effects against SARS-CoV-2, MERS-CoV, and SARS-CoV. This review provides useful information for vaccine evaluation and analysis. View Full-Text
Keywords: SARS-CoV-2; MERS-CoV; SARS-CoV; vaccine; neutralizing antibody SARS-CoV-2; MERS-CoV; SARS-CoV; vaccine; neutralizing antibody
Show Figures

Figure 1

MDPI and ACS Style

Yu, S.; Chen, K.; Fang, L.; Mao, H.; Lou, X.; Li, C.; Zhang, Y. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines 2021, 9, 588. https://doi.org/10.3390/vaccines9060588

AMA Style

Yu S, Chen K, Fang L, Mao H, Lou X, Li C, Zhang Y. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines. 2021; 9(6):588. https://doi.org/10.3390/vaccines9060588

Chicago/Turabian Style

Yu, Sicong, Keda Chen, Lei Fang, Haiyan Mao, Xiuyu Lou, Chaonan Li, and Yanjun Zhang. 2021. "Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans" Vaccines 9, no. 6: 588. https://doi.org/10.3390/vaccines9060588

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop